Become familiarised with pharmacodynamic drug interactions, get comprehensively informed about in vitro and vivo aspects of the ICH M12 drug interaction guidelines, build up knowledge on biomarkets for detecting clinical DDIs and hear the latest update on FDA scientific efforts.

Dr Jorg Taubel, CEO ofRichmond Pharmacology will be attending.

Latest news

Patient safety is not an afterthought. Explore our new infographic!

September 17, 2025
Patient safety is not an afterthought; it is the foundation of every clinical trial.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event